Cover Image
Market Research Report

Global Anti-Nuclear Antibody Test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Published by Data Bridge Market Research Private Limited Product code 610294
Published Content info 248 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Anti-Nuclear Antibody Test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
Published: February 18, 2018 Content info: 248 Pages
Description

Global anti-nuclear antibody test market is expected to reach USD 1,964.47 million by 2025 from USD 1,093.40 million in 2017, at a CAGR of 7.7% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.

The key market players for global anti-nuclear antibody test market are listed below:

  • Bio-Rad Laboratories, Inc.
  • Alere, Inc.
  • Trinity Biotech
  • Thermo Fisher Scientific Inc.
  • Antibodies Inc.
  • EUROIMMUN AG
  • Immuno Concepts

The market is further segmented into:

  • Product
  • Test
  • Disease
  • End-user

The global anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the global anti-nuclear antibody test market with 56.4% market share and is expected to reach USD 1,122.30 million by 2025, with the highest CAGR of 7.9% in the forecast period 2018 to 2025.

The global anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, Indirect Immunofluorescence is expected to dominate the global anti-nuclear antibody test market with 53.3% market share and is expected to reach USD 998.35 million by 2025, with the CAGR of 7.0% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 9.0% in the forecast period, and is expected to reach USD 406.29 million in 2025 from USD 205.60 million in 2017.

The global anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, Systemic Lupus Erythematosus is expected to dominate the global anti-nuclear antibody test market with 37.6% market share and is expected to reach USD 766.06 million by 2025, at the highest CAGR of 8.3% in the forecast period 2018 to 2025.

The global anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the global anti-nuclear antibody test market with 53.4% market share and is expected to reach USD 1,062.43 million by 2025, at the highest CAGR of 7.9% in the forecast period 2018 to 2025.

Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa.

Based on geography, the global anti-nuclear antibody test market is segmented into geographical regions, such as,

  • North- America,
  • South America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

Covered in this report:

The report covers the present scenario and the growth prospects of the global anti-nuclear antibody test for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. OVERVIEW OF GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET
  • 1.4. CURRENCY AND PRICING
  • 1.5. LIMITATION
  • 1.6. MARKETS COVERED

2. MARKET SEGMENTATION

  • 2.1. MARKETS COVERED
  • 2.2. GEOGRAPHIC SCOPE
  • 2.3. YEARS CONSIDERED FOR THE STUDY
  • 2.4. CURRENCY AND PRICING
  • 2.5. RESEARCH METHODOLOGY
  • 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7. SECONDARY SOURCES
  • 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

  • 3.1. DRIVERS
    • 3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES
    • 3.1.2. RISING MEDICAL INSURANCE
    • 3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION
  • 3.2. RESTRAINTS
    • 3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL
  • 3.3. OPPORTUNITIES
    • 3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE
    • 3.3.2. EMERGING MARKETS
    • 3.3.3. LABORATORY AUTOMATION FAVORS THE MARKET
  • 3.4. CHALLENGES
    • 3.4.1. LACK OF SKILLED PROFESSIONALS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

  • 6.1. OVERVIEW
  • 6.2. ASSAY KITS & REAGENTS
  • 6.3. SYSTEMS
  • 6.4. SOFTWARE

7. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST

  • 7.1. OVERVIEW
  • 7.2. INDIRECT IMMUNOFLUORESCENCE
  • 7.3. ELISA
  • 7.4. MULTIPLEX TESTING

8. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE

  • 8.1. OVERVIEW
  • 8.2. RHEUMATOID ARTHRITIS
  • 8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
  • 8.4. SJOGREN'S SYNDROME
  • 8.5. SCLERODERMA
  • 8.6. POLYMYOSITIS
  • 8.7. OTHERS

9. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER

  • 9.1. OVERVIEW
  • 9.2. HOSPITALS
  • 9.3. CLINICS
  • 9.4. PHYSICIAN OFFICE LABORATORIES
  • 9.5. OTHERS

10. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY GEOGRAPHY

  • 10.1. OVERVIEW
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
    • 10.2.3. MEXICO
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. FRANCE
    • 10.3.3. U.K.
    • 10.3.4. ITALY
    • 10.3.5. SPAIN
    • 10.3.6. SWITZERLAND
    • 10.3.7. NETHERLANDS
    • 10.3.8. BELGIUM
    • 10.3.9. RUSSIA
    • 10.3.10. TURKEY
    • 10.3.11. REST OF EUROPE
  • 10.4. ASIA-PACIFIC
    • 10.4.1. CHINA
    • 10.4.2. JAPAN
    • 10.4.3. INDIA
    • 10.4.4. SOUTH KOREA
    • 10.4.5. AUSTRALIA
    • 10.4.6. SINGAPORE
    • 10.4.7. THAILAND
    • 10.4.8. MALAYSIA
    • 10.4.9. INDONESIA
    • 10.4.10. PHILIPPINES
    • 10.4.11. REST OF ASIA-PACIFIC
  • 10.5. SOUTH AMERICA
    • 10.5.1. BRAZIL
    • 10.5.2. REST OF SOUTH AMERICA
  • 10.6. MIDDLE EAST & AFRICA
    • 10.6.1. SOUTH AFRICA
    • 10.6.2. REST OF MIDDLE EAST & AFRICA

11. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET,

COMPANY LANDSCAPE 220

  • 11.1. COMPANY SHARE ANALYSIS: GLOBAL
  • 11.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 11.3. COMPANY SHARE ANALYSIS: EUROPE
  • 11.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC

12. COMPANY PROFILES

  • 12.1. THERMO FISHER SCIENTIFIC INC.
    • 12.1.1. COMPANY OVERVIEW
    • 12.1.2. THERMO FISHER SCIENTIFIC INC.:REVENUE ANALYSIS
    • 12.1.3. PRODUCT PORTFOLIO
    • 12.1.4. RECENT DEVELOPMENTS
  • 12.2. MERCK KGAA
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. MERCK KGAA: REVENUE ANALYSIS
    • 12.2.3. PRODUCT PORTFOLIO
    • 12.2.4. RECENT DEVELOPMENTS
  • 12.3. ALERE INC.
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. ALERE INC.: REVENUE ANALYSIS
    • 12.3.3. PRODUCT PORTFOLIO
    • 12.3.4. RECENT DEVELOPMENTS
  • 12.4. TRINITY BIOTECH
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. TRINITY BIOTECH: COMPANY OVERVIEW
    • 12.4.3. PRODUCT PORTFOLIO
    • 12.4.4. RECENT DEVELOPMENTS
  • 12.5. ANTIBODIES INC.
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. ANTIBODIES INC.: REVENUE ANALYSIS
    • 12.5.3. PRODUCT PORTFOLIO
    • 12.5.4. RECENT DEVELOPMENTS
  • 12.6. BIO-RAD LABORATORIES, INC.
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
    • 12.6.3. PRODUCT PORTFOLIO
    • 12.6.4. RECENT DEVELOPMENTS
  • 12.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. PERKINELMER INC.: REVENUE ANALYSIS
    • 12.7.3. PRODUCT PORTFOLIO
    • 12.7.4. RECENT DEVELOPMENTS
  • 12.8. IMMUNO CONCEPTS
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. IMMUNO CONCEPTS: COMPANY SNAPSHOT
    • 12.8.3. PRODUCT PORTFOLIO
    • 12.8.4. RECENT DEVELOPMENTS

  • 12.9. INOVA DIAGNOSTICS
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. INOVA DIAGNOSTICS:COMPANY SNAPSHOT
    • 12.9.3. PRODUCT PORTFOLIO
    • 12.9.4. RECENT DEVELOPMENTS
  • 12.10. ZEUS SCIENTIFIC, INC.
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT
    • 12.10.3. PRODUCT PORTFOLIO
    • 12.10.4. RECENT DEVELOPMENTS
  • 12.11. MBL INTERNATIONAL
    • 12.11.1. COMPANY OVERVIEW
    • 12.11.2. MBL INTERNATIONAL: COMPANY SNAPSHOT
    • 12.11.3. PRODUCT PORTFOLIO
    • 12.11.4. RECENT DEVELOPMENTS
  • 12.12. MEDSOURCE OZONE BIOMEDICALS PVT. LTD
    • 12.12.1. COMPANY OVERVIEW
    • 12.12.2. MEDSOURCE OZONE BIOMEDICALS PVT. LTD: COMPANY SNAPSHOT
    • 12.12.3. PRODUCT PORTFOLIO
    • 12.12.4. RECENT DEVELOPMENTS
  • 12.13. AESKU GROUP GMBH & CO. KG
    • 12.13.1. COMPANY OVERVIEW
    • 12.13.2. AESKU GROUP GMBH & CO. KG: COMPANY SNAPSHOT
    • 12.13.3. PRODUCT PORTFOLIO
    • 12.13.4. RECENT DEVELOPMENTS

13. RELATED REPORTS

LIST OF TABLES

TABLE LIST

TABLE 1 PREVALENCE OF FEW AUTOIMMUNE DISEASESIN U.S. (2012) 37

TABLE 2 PROJECT FUNDING FOR RHEUMATOID ARTHRITIS AND LUPUS

(2018-2023) (USD MILLION) 39

TABLE 3 HEALTHCARE EXPENDITURE IN ASIA PACIFIC (USD MILLION) 42

TABLE 4 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 57

TABLE 5 GLOBAL ASSAY KITS & REAGENTS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 58

TABLE 6 GLOBAL SYSTEMS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 59

TABLE 7 GLOBAL SOFTWARES MARKET, BY REGION, 2016 - 2025 (USD MILLION) 60

TABLE 8 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST,

2016 - 2025 (USD MILLION) 63

TABLE 9 GLOBAL INDIRECT IMMUNOFLUORESCENCE MARKET, BY REGION,

2016 - 2025 (USD MILLION) 64

TABLE 10 GLOBAL ELISA MARKET, BY REGION, 2016 - 2025 (USD MILLION) 65

TABLE 11 GLOBAL MULTIPLEX TESTING MARKET, BY REGION,

2016 - 2025 (USD MILLION) 66

TABLE 12 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 69

TABLE 13 GLOBAL RHEUMATOID ARTHRITIS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 70

TABLE 14 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 71

TABLE 15 GLOBAL SJOGREN'S SYNDROME MARKET, BY REGION,

2016 - 2025 (USD MILLION) 72

TABLE 16 GLOBAL SCLERODERMA MARKET, BY REGION,

2016 - 2025 (USD MILLION) 73

TABLE 17 GLOBAL POLYMYOSITIS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 74

TABLE 18 GLOBAL OTHERS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 75

TABLE 19 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 78

TABLE 20 GLOBAL HOSPITALS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 79

TABLE 21 GLOBAL CLINICS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 80

TABLE 22 GLOBAL PHYSICIAN OFFICE LABORATORIES MARKET, BY REGION,

2016 - 2025 (USD MILLION) 81

TABLE 23 GLOBAL OTHERS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 82

TABLE 24 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY REGION,

2016 - 2025 (USD MILLION) 90

TABLE 25 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY, 2016-2025 (USD MILLION) 97

TABLE 26 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 97

TABLE 27 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 98

TABLE 28 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 99

TABLE 29 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 100

TABLE 30 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 101

TABLE 31 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 101

TABLE 32 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 102

TABLE 33 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 103

TABLE 34 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 104

TABLE 35 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 104

TABLE 36 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 105

TABLE 37 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 106

TABLE 38 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 107

TABLE 39 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 107

TABLE 40 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 108

TABLE 41 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 109

TABLE 42 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY,

2016-2025 (USD MILLION) 116

TABLE 43 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 117

TABLE 44 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 117

TABLE 45 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 118

TABLE 46 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 119

TABLE 47 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 120

TABLE 48 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 120

TABLE 49 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 121

TABLE 50 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 122

TABLE 51 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 123

TABLE 52 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 123

TABLE 53 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 124

TABLE 54 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 125

TABLE 55 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 126

TABLE 56 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 126

TABLE 57 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 127

TABLE 58 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 128

TABLE 59 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 129

TABLE 60 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 129

TABLE 61 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 130

TABLE 62 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 131

TABLE 63 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 132

TABLE 64 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 132

TABLE 65 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 133

TABLE 66 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 134

TABLE 67 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 135

TABLE 68 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 135

TABLE 69 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 136

TABLE 70 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 137

TABLE 71 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 138

TABLE 72 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 138

TABLE 73 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 139

TABLE 74 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 140

TABLE 75 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 141

TABLE 76 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 141

TABLE 77 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 142

TABLE 78 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 143

TABLE 79 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 144

TABLE 80 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 144

TABLE 81 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 145

TABLE 82 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 146

TABLE 83 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 147

TABLE 84 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 147

TABLE 85 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 148

TABLE 86 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 149

TABLE 87 REST OF EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 150

TABLE 88 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY, 2016-2025 (USD MILLION) 157

TABLE 89 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 158

TABLE 90 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 158

TABLE 91 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 159

TABLE 92 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 160

TABLE 93 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 161

TABLE 94 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 161

TABLE 95 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 162

TABLE 96 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 163

TABLE 97 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 164

TABLE 98 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 164

TABLE 99 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 165

TABLE 100 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 166

TABLE 101 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 167

TABLE 102 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 168

TABLE 103 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 168

TABLE 104 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 169

TABLE 105 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 170

TABLE 106 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 170

TABLE 107 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 171

TABLE 108 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 172

TABLE 109 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 173

TABLE 110 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 173

TABLE 111 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 174

TABLE 112 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 175

TABLE 113 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 176

TABLE 114 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 176

TABLE 115 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 177

TABLE 116 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 178

TABLE 117 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 179

TABLE 118 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 179

TABLE 119 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 180

TABLE 120 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 181

TABLE 121 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 182

TABLE 122 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 182

TABLE 123 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 183

TABLE 124 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 184

TABLE 125 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 185

TABLE 126 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 185

TABLE 127 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 186

TABLE 128 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 187

TABLE 129 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 188

TABLE 130 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 188

TABLE 131 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 189

TABLE 132 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 190

TABLE 133 REST OF ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 191

TABLE 134 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY, 2016-2025 (USD MILLION), 198

TABLE 135 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT, 2016 - 2025 (USD MILLION) 198

TABLE 136 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY TEST, 2016 - 2025 (USD MILLION) 199

TABLE 137 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY DISEASE, 2016 - 2025 (USD MILLION) 200

TABLE 138 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY END USER, 2016 - 2025 (USD MILLION) 201

TABLE 139 BRAZIL ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT, 2016 - 2025 (USD MILLION) 202

TABLE 140 BRAZIL ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY TEST, 2016 - 2025 (USD MILLION) 202

TABLE 141 BRAZIL ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY DISEASE, 2016 - 2025 (USD MILLION) 203

TABLE 142 BRAZIL ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY END USER, 2016 - 2025 (USD MILLION) 204

TABLE 143 REST OF SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT, 2016 - 2025 (USD MILLION) 205

TABLE 144 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY, 2016-2025 (USD MILLION), 212

TABLE 145 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT, 2016 - 2025 (USD MILLION) 212

TABLE 146 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY TEST, 2016 - 2025 (USD MILLION) 213

TABLE 147 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY DISEASE, 2016 - 2025 (USD MILLION) 214

TABLE 148 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY END USER, 2016 - 2025 (USD MILLION) 215

TABLE 149 SOUTH AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT, 2016 - 2025 (USD MILLION) 216

TABLE 150 SOUTH AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY TEST, 2016 - 2025 (USD MILLION) 216

TABLE 151 SOUTH AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY DISEASE, 2016 - 2025 (USD MILLION) 217

TABLE 152 SOUTH AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY END USER, 2016 - 2025 (USD MILLION) 218

TABLE 153 REST OF MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT, 2016 - 2025 (USD MILLION) 219

LIST OF FIGURES

FIGURES LIST

FIGURE 1 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: SEGMENTATION 27

FIGURE 2 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: DATA TRIANGULATION 30

FIGURE 3 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET : RESEARCH SNAPSHOT 31

FIGURE 4 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET : BOTTOM UP APPROACH 32

FIGURE 5 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: TOP DOWN APPROACH 32

FIGURE 6 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET :

INTERVIEW DEMOGRAPHICS 33

FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF

GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET 36

FIGURE 8 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET : SEGMENTATION 46

FIGURE 9 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR ANTI-NUCLEAR ANTIBODY TEST AND ASIA PACIFIC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2018 TO 2025 47

FIGURE 10 INCREASING INCIDENCE OF AUTOIMMUNE DISEASES, RISING MEDICAL INSURANCE ARE EXPECTED TO DRIVE THE MARKET FOR ANTI-NUCLEAR ANTIBODY TEST MARKET IN THE FORECAST PERIOD 2018 TO 2025 48

FIGURE 11 ASSAY KITS & REAGENTS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET IN 2018 & 2025 49

FIGURE 12 ASIA PACIFIC IS THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR ANTI-NUCLEAR ANTIBODY TEST MANUFACTURERS IN THE FORECAST PERIOD FROM 2018 TO 2025 50

FIGURE 13 PREVALENCE OF RHEUMATOID ARTHRITIS IN FEW COUNTRIES (2015) 51

FIGURE 14 PREVALENCE OF SYSTEMIC LUPUS ERYTHEMATOSUS IN FEW

COUNTRIES (2015) 52

FIGURE 15 PREVALENCE OF SJOGREN'S SYNDROME IN FEW COUNTRIES (2015) 53

FIGURE 16 PREVALENCE OF SCLERODERMA IN FEW COUNTRIES (2015) 54

FIGURE 17 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY PRODUCT TYPE, 2017 56

FIGURE 18 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY TEST, 2017 62

FIGURE 19 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY DISEASE, 2017 68

FIGURE 20 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY END USER, 2017 77

FIGURE 21 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET SNAPSHOT (2017) 85

FIGURE 22 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2017) 86

FIGURE 23 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2018) 87

FIGURE 24 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017 & 2025) 88

FIGURE 25 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET:

BY PRODUCT TYPE (2018 & 2025) 89

FIGURE 26 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) 92

FIGURE 27 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET:

BY COUNTRY (2017) 93

FIGURE 28 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET :

BY COUNTRY (2018 & 2025) 94

FIGURE 29 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY (2018 & 2025) 95

FIGURE 30 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT (2018 & 2025) 96

FIGURE 31 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) 111

FIGURE 32 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) 112

FIGURE 33 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET :

BY COUNTRY (2018 & 2025) 113

FIGURE 34 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY (2017 & 2025) 114

FIGURE 35 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT (2018 & 2025) 115

FIGURE 36 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) 152

FIGURE 37 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) 153

FIGURE 38 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET :

BY COUNTRY (2018 & 2025) 154

FIGURE 39 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY (2017 & 2025) 155

FIGURE 40 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT (2018 & 2025) 156

FIGURE 41 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) 193

FIGURE 42 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET:

BY COUNTRY (2017) 194

FIGURE 43 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET :

BY COUNTRY (2018 & 2025) 195

FIGURE 44 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY (2017 & 2025) 196

FIGURE 45 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT (2018 & 2025) 197

FIGURE 46 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET:

SNAPSHOT (2017) 207

FIGURE 47 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET:

BY COUNTRY (2017) 208

FIGURE 48 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET :

BY COUNTRY (2018 & 2025) 209

FIGURE 49 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY (2017 & 2025) 210

FIGURE 50 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT (2018 & 2025) 211

FIGURE 51 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%) 220

FIGURE 52 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET:

COMPANY SHARE 2017 (%) 221

FIGURE 53 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%) 222

FIGURE 54 ASIA PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET:

COMPANY SHARE 2017 (%) 223

Back to Top